Source comparison
ARA-290 Dosage Neuropathy 2026: Comparison of Published Protocols
Sarcoidosis SFN (Annals of Neurology 2015) 4 3×/week SC Corneal nerve fiber density (CNFD) +1.2 fibers/mm² vs +0.1 placebo Proof-of-concept established; short duration limits long-term efficacy conclusions Diabetic neuropathy (Diabetes Care 2017) 4 vs 8 12 IEN
This comparison does not assign a generated winner or score.
- Sarcoidosis SFN (Annals of Neurology 2015)
- 4
- 3×/week SC
- Corneal nerve fiber density (CNFD)
- +1.2 fibers/mm² vs +0.1 placebo
- Proof-of-concept established; short duration limits long-term efficacy conclusions
- Diabetic neuropathy (Diabetes Care 2017)
- 4 vs 8
- 12
- IENFD and pain (NRS)
- 8mg reduced pain by 2.4 points; 4mg by 1.8 points
- Higher dose showed marginal benefit but increased injection site reactions; 4mg optimal for tolerability
- Paclitaxel CIPN prevention (Phase 2, 2019)
- 6
- 8 (concurrent + post-chemo)
- Peak pain during chemo, IENFD at 3 months
- Lower acute pain (4.2 vs 5.8 NRS); no IENFD difference at 3 months
- Suggests transient effect without sustained dosing; prophylactic use requires extended protocols
- Idiopathic SFN (open-label, 2020)
- Pain reduction (SFN-SIQ)
- 40% responder rate (≥30% pain reduction)
- Heterogeneous etiology cohort limits interpretation; responders likely had inflammatory-driven SFN
- Araim Phase 2b dose-ranging (unpublished, 2021)
- 1, 4, 8, 12
- IENFD, pain, QOL
- 8mg optimal; 12mg no additional benefit, more reactions
- Ceiling effect confirmed; doses >8mg not justified